Essex Bio-Technology Reports Profit Decline but Strong Balance Sheet in First-Half 2026

Essex Bio-Technology ( (HK:1061) ) just unveiled an update.

Essex Bio-Technology reported a weaker first half for 2026, with turnover falling 10.5% to HK$784.7 million and profit for the period dropping 32.2% to HK$110.7 million, reflecting pressure on margins as gross profit margin slipped to 83.6% and net profit margin to 14.1%. Earnings per share declined to HK19.53 cents and the interim dividend was cut to HK5.0 cents, but the group maintained a solid balance sheet, with total assets up 3.6%, net assets rising 5.6% and a stable gearing ratio of 0.30, suggesting continued financial resilience despite short-term profitability challenges.

The company’s cash and cash equivalents edged higher to HK$806.6 million and its current ratio improved to 2.15, underscoring strong liquidity to support ongoing operations and potential investment needs. While return on equity fell to 4.3% from 7.2% amid lower earnings, the strengthened equity base and modest reduction in liabilities indicate Essex Bio-Technology remains conservatively financed, which may help it navigate market headwinds and preserve its position in the competitive biopharmaceutical industry.